(Q80419720)
Statements
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160 (English)
Kenneth H Mayer
Barney S Graham
Beryl A Koblin
Susan P Buchbinder
Mark J Mulligan
Connie L Celum
Robert B Belshe
M Juliana McElrath
Haynes W Sheppard
Peter B Gilbert
Michael C Keefer
Deborah Lee